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Background: It is generally accepted that intratympanic injection provides an effective 
approach to manage severe vertigo in Ménière’s disease. Although there are several 
medications available, that which is the most effective is still subject to debate.  
Objective: To assess the effectiveness and safety of the different medications used in 
treatment of Ménière’s disease by intratympanic injection using a network meta-analysis. 
Methods: PubMed, EMBASE, CINAHL and CENTRAL were searched. Only randomized 
controlled trials that compared the effectiveness of medications used for intratympanic 
injection to treat Ménière’s disease with each other or a placebo were included. The primary 
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symptoms. The effectiveness was expressed in terms of risk ratio (RR) with a 95% credible 
interval (CrI) for individual studies analyzed. Network meta-analyses was performed by Stata 
version 15.0 using the network package. 
Results: Nine studies involving 314 patients treated with 5 different medications were 
included in the present analysis. Number of injections given varied from 1 to 10 and 
follow-up time from 3 to 28 months. When compared to each other or to a placebo, 
Gentamicin was found to be the most efficacious medication, followed by 
Methylprednisolone, Latanoprost, Dexamethasone and Ganciclovir in order of effectiveness. 
However, no significant difference in efficacy was found between Gentamicin and 
Methylprednisolone when outcomes from studies with a follow-up time equal to or more than 
24 months were analyzed. It was not possible to conduct subgroup and sensitivity analysis 
because of the limited number of studies that were included. 
Conclusion: All medications are more effective than a placebo in the treatment of Ménière’s 
disease by intratympanic injection. According to the SUCRA, Gentamicin ranked the most 
effective, with Gentamicin and Methylprednisolone equally effective in the long-term. When 
the potential risk of hearing loss induced by Gentamicin is taken into consideration, 
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Key points: 
 There is currently no consistent guidance as to the most effective method to treat 
Ménière’s disease, however, it is generally accepted that intratympanic injection provides 
an effective way to manage severe vertigo in the acute phase of repeated attack. 
 This network meta-analysis shows that all medications are more effective than a placebo 
for the treatment of Ménière’s disease by intratympanic injection. According to the 
SUCRA, Gentamicin ranked as the most effective with the efficacy of Gentamicin and 
Methylprednisolone similar in terms of their long-term effect. 
 Considering the potential risk of hearing loss induced by Gentamicin, 




Meniere’s disease is a common disorder characterized by recurrent episodes of 
spontaneous vertigo, fluctuating hearing loss and tinnitus, often with a feeling 
of fullness in the ear. Because of different diagnostic criteria, especially in the 
early stages, prevalence figures differ widely from 10 to 513 per 100,000 
population.
1-6
 A number of important aetiological factors have been implicated 
in the development of Ménière’s disease such as; stress, dyssomnia, allergies, 
immune dysfunction, autonomic dysfunction, poor mental health, and even 
atmospheric pressure.
7-10
 Symptoms associated with Meniere’s disease also 
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The pathophysiology underlying Meniere’s disease is suggested as  
endolymphatic hydrops,
12
 most likely due to an abnormality in the absorption of 
endolymph at the endolymphatic sac,
13
 a hypoplasia of the vestibular 
aqueduct,
14
 a genetic predisposition to anatomic abnormality
15
 or a reactivation 
of latent herpes simplex virus
16




Ménière’s disease has a considerable effect on a person's quality of life, as a 
result of its symptoms. The primary aim of treatment however is to reduce the 
number of episodes and severity of vertigo. Amelioration of aural symptoms 
(e.g., hearing loss, aural pressure and tinnitus) is also taken into consideration 
by clinicians. Efficient and specific treatment options are limited at present. For 
example, the study by Manzoor et al.
18
 suggests that Ménière’s disease is a 
multifactorial disorder and no single treatment can provide relief in all patients 
at the initial phase of the disease. Currently it is generally accepted that 
intratympanic injection provides an effective way to manage severe vertigo
19
 in 
the acute phase where there are repeated episodes.  
Two Cochrane systematic reviews by Phillips et al.
20
 and Pullens et al.
21
 
assessed the effectiveness of intratympanic injections in the treatment of vertigo 
in Ménière’s disease. Although their conclusion suggests that intratympanic 
injection of either gentamicin or steroid appears effective, this work requires 
updating to include several new clinical trials.
22,23
 Moreover, there is an urgent 
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individual medications by direct comparisons. This would contribute greatly to 
the development of more clear clinical guidance on medications used for the 
management of Ménière's disease using intratympanic injection.  
The purpose of this systematic review is to assess the effectiveness and safety of 
different medications used in intratympanic injection for Ménière’s disease by a 
network meta-analysis. Network meta-analysis is a statistical tool that enables 
information from different trials that address the same variables but using 
different interventions to be analyzed. It has been used to compare different 
treatments with each other and with a placebo, allowing direct and indirect 
comparison between these different interventions. To the best of our knowledge, 
this is the first network meta-analysis to address the efficacy of different 
medications used in intratympanic injection for Ménière’s disease. 
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2. Methods 
2.1 Criteria for study consideration 
2.1.1 Types of studies 
Only randomized controlled trials (RCTs) were included in this systematic 
review. 
 
2.1.2 Characteristics of participants 
All patients diagnosed with Ménière’s disease according to the diagnostic 
guidelines of the American Academy of Otolaryngology - Head and Neck 
Surgery (AAO-HNS) in 1995
24
 were included. 
 
2.1.3 Types of interventions 
All studies that described the effectiveness of a medication, when compared to a 
placebo, in intratympanic injection were included. We also included studies that 
provided direct comparison of the effectiveness of medications used in 
intratympanic injection. 
 
2.2 Types of outcome measures 
Effectiveness of vertigo symptom management was used as the primary 
outcome as suggested by the AAO-HNS 1995. In addition, other outcomes were 
considered, including changes to hearing thresholds, severity of tinnitus, felling 
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2.3 Search strategy for identifying studies 
2.3.1 Electronic database searches 
The database of PubMed, EMBASE, CINAHL and CENTRAL were searched. 
We used combined terms of Medical Subject Headings (MeSH), keywords or 
free text words to model search strategies and the search strategies were adapted 
to the requirements of each database.  
 
2.3.2 Searching other resources 
In addition, manual searches were made for relevant references from identified 
publications as well as abstracts from scientific meetings over the last five years 
from relevant groups (e.g., British Society of Audiology, Bárány Society, 
European Academy of Otology and Neurotology (EAONO), American 
Academy of Otolaryngology-Head and Neck Surgery (AAO--HNS), Japan 
Society for Equilibrium Research and Korean Balance Society) to avoid 
searching bias. 
 
2.4 Data collection and analysis 
2.4.1 Selection of studies 
Two authors (ZC, FY) independently examined the titles and abstracts of studies 
identified using the search strategy mentioned above to check relevance. After 
reviewing the full text of articles, relevant studies were identified and included 
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not be solved after discussion, led to arbitration provided by one of the other 
authors (FZ, WH).  
 
2.4.2 Data extraction and management 
Two authors (ZC, WH) independently used an agreed data collection form to 
extract data from the included studies. Data extracted was double checked for 
accuracy, and any disagreements after discussion arbitrated by one of the other 
authors (FZ, FY). Attempts were made to contact the corresponding authors for 
additional information on outcomes that were needed but not reported in the 
studies. 
 
2.5 Assessment of risk of bias in included studies 
Two authors (FY, WH) independently followed the guidance in the Cochrane 
Handbook for Systematic Reviews of Interventions
25
 to assess risk of bias in the 
included studies. Any disagreements after discussion was arbitrated by one of 
the other authors (FZ, ZC).  
 
2.6 Ethical considerations 
No ethical approvals were required for this review as no patients and public 
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3. Data analysis 
We expressed medication effectiveness in terms of risk ratio (RR) with a 95% 
credible interval (CrI) for individual studies with count outcomes, e.g. the 
number of patients with no vertigo complaints after treatment. Network 
meta-analysis with a consistency model was undertaken to compare different 
medications for intratympanic injection for Ménière’s disease. A network plot 
obtained from Stata software was used to ensure that trials were connected by 
interventions and any trials that were not connected were excluded. To assess 
inconsistency,
26,27
 inconsistency factor (IF) plots created by Stata software were 
used. The ranking probabilities for all interventions was estimated.  
The surface under the cumulative ranking curve (SUCRA) (cumulative 
probability) and relative ranking table with CrI for the ranking probabilities was 
calculated.
27,28
 Sensitivity analysis was gained by excluding studies at high risk 
of bias to assess the robustness of the analyses. Subgroup analysis was also 
conducted according to the type of medication and follow-up time. Possible 
presence of publication bias or small-study bias was checked for using funnel 
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3. Results 
3.1 Studies retrieved and summary  
537 studies were identified by the literature search strategies. Of these, 116 
studies were duplicates. From the remainder, 367 were removed after screening 
titles and abstracts. Full texts of 54 records were read to assess their eligibility, 
11 were considered. Of these, 2 were excluded because they described clinical 
trials of OTO-104, which is not available clinically. Although several ongoing 
studies were identified, unfortunately no detailed information was disclosed by 
the authors for further analysis. As a result, nine studies were eventually 
included in the present analysis. Figure 1 shows the study selection process in a 
PRISMA flow diagram.  
Table 1 summarises the characteristics of the included studies for the network 
meta-analysis. The 9 studies were published between 2004 and 2017, and a total 
of 314 patients participated in these studies, which were conducted in seven 
countries. Among these studies, five individual medications were used for 
intratympanic injection for Ménière’s disease. They were Gentamicin, 
Dexamethasone, Methylprednisolone, Ganciclovir and Latanoprost. Of these, 
Gentamicin was the most commonly used. Three studies
30-32
 compared the 
effectiveness between Gentamicin and placebo, whilst a further 3 studies
33-35
 
compared the effectiveness of Gentamicin, Dexamethasone and 
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the effectiveness of Dexamethasone, Ganciclovir and Latanoprost against a 
placebo.  
The number of injections given varied from 1 to 10 and follow–up time varied 
between 3 and 28 months for all included studies except that of Rask-Andersen 
et al.
36
, which revealed outcomes at 2 weeks after injection only. In the 2 
studies
33,37
 where results were measured at different follow-up times, the results 
from the last measurement was used for analysis, as recommended by 
AAO–HNS.   
All of the included studies reported the primary outcome, i.e., the effectiveness 
of vertigo symptom management. Four
32,33,35,38
 reported outcomes in terms of 
vertigo numeric scale value based on AAO–HNS criteria, four
30,31,34,37
 reported 
the number of patients with no vertigo complaints, whilst the last study
36
 only 
presented the individual VAS scores of vertigo in their figures, from which can 
identify how many patients experienced significant improvement. The other 
outcomes assessing vertigo, such as DHI, VSS or SI scores, were reported only 
by two studies.
34,39
 In this situation, effect was expressed in terms of risk ratio 
(RR) with 95% credible interval (CrI) for the primary outcome analysis. 
However, due to limited information on other outcomes, no further analysis was 











This article is protected by copyright. All rights reserved. 
As shown in Figure 2, the overall quality of studies in GRADE assessment was 
moderate. Only one trial
34
 was judged to have no risk of bias, two studies
31,33
 
were judged high risk and the others moderate risk. Most had evidence of high 
risk or unclear risk of bias in terms of the random sequence generation as only 3 
studies
32,34,37
 clearly described their random sequence generation procedures. 
There was also other bias in one trial as they did not finish their study.  
 
Network graphs of all the eligible comparisons for the primary outcomes are 
presented in Figure 3. The width of the lines is proportional to the number of 
trials comparing every pair of treatments, and the size of every circle is 
proportional to the sample size. There are more trials and patients comparing 
gentamicin to placebo and two loops in which each medication has direct trial 
comparisons with at least two other medications. A global inconsistency test 
was then performed in the loops shown in Figure 4, which suggested no 
evidence of inconsistency of treatments for the primary outcomes.  
 
Pairwise comparison is presented in a league table as shown in Table 2. The 
surface under the cumulative ranking curve (SUCRA) is shown in Table 3. In all 
of the included studies, there was high-certainty of evidence of benefit for all 
medications when compared to placebo. The rankograms showed Gentamicin as 
the most efficacious medication when compared to the others, followed by 
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possible to conduct subgroup and sensitivity analysis because of the limited 
number of included studies. However, no significant difference was found 
between Gentamicin and Methylprednisolone in terms of efficacy when the 
outcomes obtained from studies having follow-up times equal to or more than 
24 months were used (Table 4). In respect of the safety of these medications, 
especially the effect on hearing, no definite conclusions can be drawn due to the 
lack of data in the included studies. The funnel plot in Figure 5 suggests that the 




Although the present review shows that all medications are more effective than 
placebo for the treatment of Ménière’s disease, the included medications were 
not equivalent, according to the SUCRA. Gentamicin ranked as the most 
effective with Methylprednisolone ranked second, followed by Latanoprost, 
Dexamethasone and Ganciclovir in that order. However, caution is needed to 
interpret the effectiveness of Latanoprost as results were obtained from the only 
study using Latanoprost that recruited only 9 patients even though a 
placebo-controlled double-blind study design was adopted in that trial. In 
addition, since Ménière’s disease is a chronic illness and also a fluctuating 
disease with a strong placebo effect, it is suggested that attention should be paid 
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months’ follow-up time was excluded, the efficacy of Gentamicin and 
Methylprednisolone were similar.  
The most common and effective intratympanic injection medication used in the 
treatment of Ménière’s disease so far is Gentamicin. However, Gentamicin has 
an ototoxic effect that causes direct damage to the sensorineural epithelium and 
hair cells of the labyrinth, and thereby affects vestibular and cochlear function.
40
 
Although use of Gentamicin has become increasingly popular since its 
introduction in 1981,
41
 the risk of damaging cochlear function has led to the 
adoption of a variety of injection dosing schedules and treatment duration to 
minimize risk. There remains no current consensus on clinical guidelines for the 
use of Gentamicin in terms of dose and duration.
42,43
 The alternative approach of 
using steroids has been suggested as a better option due to its immunoregulatory 
function and anti-inflammatory effects and the absence of severe side effects on 
inner ear function. Several prospective, randomized, double-blind, placebo 





) versus placebo with inner ear perfusion. The results 
showed that steroids provided better intervention in terms of managing the 
vertigo symptoms.  
Furthermore, Patel
34
 compared the effectiveness of Methylprednisolone 
(62.5mg/mL) with Gentamicin and no significant difference was seen in 
controlling vertigo. Other studies have however shown negative results when 
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Such inconsistent conclusions are likely to be due to different study designs, e.g., 
type and dose of the steroids such as Methylprednisolone, OTO-104 and 
Dexamethasone. The findings of this network meta-analysis suggest that 
Gentamicin is the most effective medication for intratympanic injection for 
Ménière’s disease. However, considering the substantial risk of hearing loss 
induced by Gentamicin, Methylprednisolone may be the more efficacious 
choice. 
The strengths of this review are that a complex network meta-analysis was 
performed to compare the efficacy of all available medications for 
intratympanic injection for Ménière’s disease in order to identify the best 
treatment. Multiple databases and reference lists were searched to identify as 
many relevant studies as possible. All the relevant studies were randomized 
controlled trials as these can avoid most kinds of bias in the design and 
implementation and strengthen the quality of analysis. Study selection, data 
extraction and quality assessment were also undertaken by two independent 
researchers with a high level of agreement to avoid selection bias.  
However, our review needs to be viewed in light of several limitations. Firstly, 
the outcomes derived from this review are certainly affected by the 
shortcomings of the included studies. There are several limitations in some of 
the included studies, such as too small a sample size to support strong external 
validity (the funnel plot indicates that our conclusion may be influenced by 
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not be as effective as suggested because only 9 patients were recruited in that 
trial.), inappropriate study design in terms of blinding, e.g. did not adopt a 
double-blind trial, and many of the trials had a short duration of follow-up time 
(the shortest follow-up time was only 2 weeks) given that Ménière is a chronic 
disease. Secondly, when planning this review, we aimed to include ongoing 
trials and indeed a number were researched, unfortunately, we had to give up 
these studies because the researchers did not reply to us with details requested. 
There may be some English language bias as well as only English literature was 
included. The last but most important limitation of this review is that we only 
analyzed the primary outcome and not the other outcomes, especially the 
unwanted hearing loss. There was substantial variation across the included 
studies in terms of outcomes assessed. Some studies used continuous variables, 
e.g., the mean increase in PTA, to assess the outcomes, whilst others used count 
outcomes, e.g., the number of patients that the hearing improved. It is not 
possible to analyze as the data types are not uniform. Future researchers should 




All medications are more effective than a placebo in the treatment of Ménière’s 
disease by intratympanic injection. According to SUCRA, Gentamicin ranked 










This article is protected by copyright. All rights reserved. 
Dexamethasone, and Ganciclovir in that order. The efficacy of Gentamicin and 
Methylprednisolone are similar in terms of their long-term effect. Considering 
the potential risk of hearing loss induced by Gentamicin, Methylprednisolone 
may be the best choice for intratympanic injection for Ménière’s disease. It is 
noteworthy that the effectiveness of Latanoprost needs to be interpreted 
cautiously due to its small sample size, even though a placebo-controlled 
double-blind study design was adopted. In future studies, more large-sample 
size and multi-center RCTs should be carried out to further validate the 
effectiveness of intratympanic injection for the treatment of Ménière’s disease. 
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Pla 5 24 Class A and B of 
vertigo control: 
11 
Class A and B of 
vertigo control: 4 
Mean increase in 
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en et al. 
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9 9 Lat Pla 6 0.5 Significant 
reduction of 
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Mean increase in 
PTA: -6 
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T: Treated group, C: Controled group 
Dex: Dexamethasone, Pla: Placebo, Lat: Latanoprost, Gen: Gentamicin, Gan: Ganciclovir, MP: Methylprednisolone  
NA: Not Available 
Class (A-F): Class of vertigo control according to the AAO-HNS committee classification, VAS: Visual Analogue Scale scores (0-100), PTA: Pure Tone Average (dB), THI: Tinnitus 
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Table 2 League table of pairwise comparisons of treatment medications in 
the network meta-analysis 
Pla      
-2.49 (-5.91,0.93) MP     
-1.95(-5.85,1.96) 0.54(-4.65,5.74) Lat    
-2.85 
(-5.25,-0.45) -0.36 (-3.12,2.41) 
-0.90 
(-5.49,3.68) Gen   




(-1.86,6.98) Gan  








Pla: Placebo, MP: Methylprednisolone, Lat: Latanoprost, Gen: Gentamicin, Gan: Ganciclovir, Dex: Dexamethasone 
 
Table 3 Effectiveness ranking by surface under cumulative ranking curve 
(SUCRA)  
Treatment SUCRA (%) Rank 
Gen 77.4 1 
MP 67.5 2 
Lat 57.4 3 
Dex 52.8 4 
Gan 28.6 5 
Pla 16.3 6 
 
Gen: Gentamicin, MP: Methylprednisolone, Lat: Latanoprost, Dex: Dexamethasone, Gan: Ganciclovir, Pla: Placebo 
 
Table 4 Rank by SUCRA only including studies with follow-up time equal 
to or more than 24 months 
Treatment SUCRA (%) Rank 
Gen 68.4 1 
MP 63.6 2 
Dex 47.2 3 
Pla 20.7 4 
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